Supply Chain | August 31, 2024
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Multidisciplinary central team deployed to assist Gujarat with epidemiological, environmental, and laboratory investigations of AES cases
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
The initiative aimed to reach and support individuals suffering from epilepsy through early detection and effective disease management
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Global Phase-3 study initiation expected in the second half of 2024
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Dalal is an experienced leader at Abbott, having joined in 1995 as a Product Manager
Subscribe To Our Newsletter & Stay Updated
